Claims
- 1. A process for detecting the presence or absence of Mycobacterium tuberculosis in a clinical isolate or a sample of body fluid comprising incubating a DNA fragment identified as SEQ ID NO:1 with the clinical isolate or sample of body fluid and detecting the presence or absence of Mycobacterium tuberculosis.
- 2. A process for detecting the presence or absence of Mycobacterium tuberculosis in a clinical isolate or sample of body fluid comprising hybridizing a DNA fragment identified as SEQ ID NO:1 with the clinical isolate or sample of body fluid and detecting the presence or absence of Mycobacterium tuberculosis.
- 3. A process as claimed in claim 2 wherein dot blot hybridization, Southern hybridization or microplate hybridization is used.
- 4. A process as claimed in claim 1 wherein before detecting the presence or absence of Mycobacterium tuberculosis primers are added to amplify the DNA of Mycobacterium tuberculosis.
- 5. A process as claimed in claim 2 wherein before detecting the presence or absence of Mycobacterium tuberculosis primers are added to amplify the DNA of Mycobacterium tuberculosis.
- 6. A process for the production and identification of a DNA fragment of Mycobacterium tuberculosis comprising 1291 base pairs identified as SEQ ID NO:1: comprising the steps of:(a) constructing a genomic library of Mycobacterium tuberculosis in a vector comprising phage lambda gt11 or a plasmid; (b) screening the genomic library of Mycobacterium tuberculosis with genomic DNA of Mycobacterium tuberculosis as a probe to select DNA fragments capable of specifically hybridizing to Mycobacterium tuberculosis genomic DNA; (c) isolating repetitive DNA fragments which have positive hybridization signals between 10 to 60 minutes; (d) hybridizing the DNA fragments isolated in step (c) with genomic DNA of mycobacteria other than Mycobacterium tuberculosis; (e) selecting DNA which did not produce any hybridization signals in step (d); and (f) detecting of Mycobacterium tuberculosis by incubating the DNA selected in step (e) with samples which may contain Mycobacterium tuberculosis, hybridizing the sample and detecting the presence of Mycobacterium tuberculosis.
- 7. A process as claimed in claim 6, wherein the DNA fragment is hybridized to mycobacterial DNA by dot blot hybridization, Southern hybridization or microplate hybridization.
- 8. A process as claimed in claim 6, wherein the samples of Mycobacterium tuberculosis are detected by hybridization and PCR amplification by adding primers selected for the DNA of step (e).
- 9. A process as claimed in claim 6 wherein the samples for Mycobacterium tuberculosis are detected by hybridization and PCR amplification by adding primers selected for the nucleotide sequence of SEQ ID NO:1.
- 10. A process as claimed in claim 1 wherein the body fluid is selected from the group consisting of sputum, cerebrospinal fluid, pleural fluid, urine, ascitic fluid, gastric samples, bronchial lavage, pericardial fluid, pus, and lymph node aspirate.
- 11. A process as claimed in claim 2, wherein the body fluid is selected from the group consisting of sputum, cerebrospinal fluid, bronchial lavage, urine, pleural fluid, pus, ascitic fluid, gastric fluid, pericardial fluid or lymph node aspirate.
- 12. A process for restriction fragment length polymorphism analysis of Mycobacterium tuberculosis clinical isolates comprising hybridizing the DNA fragment of SEQ ID NO:1 with clinical isolates containing Mycobacterium tuberculosis and analyzing the restriction fragment length polymorphism.
Parent Case Info
This is a divisional of application Ser. No. 08/997,897 filed on Dec. 24, 1997, U.S. Pat. No. 6,114,514 claims the benefit thereof and incorporates the same by refreference.
Non-Patent Literature Citations (1)
Entry |
Kiehn, T.E., Clinical Infectious Diseases, 17 (Supp 2), 1:S447-S454, (1993). |